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Introduction
Cardiovascular diseases are the leading causes of morbidity 
and mortality in the United States. Every 43 seconds an 
American experiences a myocardial infarction (MI), which 
can lead to the death of up to 1 billion cardiomyocytes in 
the left ventricle, translating to approximately 50 g of muscle 
mass.1–3 Unlike in some model organisms such as zebrafish, 
the mammalian heart has limited regenerative capacity.4 As 
a result, cardiac injury triggers a pathologic adaptive cascade 
resulting in tissue remodeling, myocyte hypertrophy, and 
eventual catastrophic heart failure.5,6 Current therapeutic 
strategies such as surgical, endovascular, and pharmacologi-
cal interventions6–9 are merely palliative in nature and do not 
adequately address the true cause of heart failure – the loss of 
functional myocytes and supporting cardiac tissue.10 As such, 
heart transplantation is the only effective treatment option 
to replace damaged or diseased myocardium. However, the 
limited number of available donors and complications from 
immune rejection of transplanted organs make cardiac trans-
plants impractical for the vast number of people affected by 
heart failure and disease.
Over the past several years, the integration of stem cell 
biology with biomaterials science has resulted in the devel-
opment of several promising strategies for the regeneration 
of various tissues and organs.11 In this review, we discuss 
the extent to which biomaterial-based approaches are aiding 
myocardial regenerative medicine efforts in the following 
ways: (i) improving the in vitro differentiation of stem cells to 
cardiomyocytes and (ii) guiding the delivery and integration 
of transplanted stem cells. We then speculate on the future of 
biomaterial-based approaches for stem cell myocardial tissue 
engineering.
Stem Cell Types for Cardiac Repair
Although a variety of mature cell types isolated from primary 
and fetal tissue sources have been used to repair the damaged 
cardiac tissue in animal models and clinical trials,12,13 this 
review focuses on the development of stem cell-based bio-
material approaches for myocardium regenerative purposes. 
Broadly speaking, stem cells are defined by two common 
characteristics: (i) the ability to self-renew or proliferate inde-
finitely and (ii) the potential to differentiate into one or more 
specialized cell types. As such, stem cells can be categorized 
into two types, which have differing differentiation poten-
tials: (i) pluripotent stem cells [PSCs; including embryonic 
stem cells (ESCs) and induced pluripotent stem cells (iPSCs)], 
which can give rise to hundreds of cell types that comprise 
the adult body, and (ii) adult stem cells, which can only dif-
ferentiate into a small subset of specialized mature cells. The 
characteristics, advantages, and limitations of each of these 
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cell sources for cardiac regenerative medicine purposes are 
summarized in Table 1.
Pluripotent stem cells. PSCs, which include ESCs and 
iPSCs, have the potential to differentiate into hundreds of 
specialized cell types that comprise the fully mature adult 
body. Although there are some slight genetic and epigenetic 
differences between ESCs and iPSCs,14,15 both the cells have 
the ability to provide the raw material that is necessary for 
cardiac tissue engineering. There are a wide variety of proto-
cols used to generate cardiomyocytes from PSC through the 
temporal addition of growth factors that mimic in vivo cardiac 
development.16–26
Embryonic stem cells. ESCs are derived from the inner cell 
mass of a preimplantation embryo. The first ESCs were iso-
lated from mouse embryos by two independent groups in the 
early 1980s.27,28 In 1998, Thomson led a group of researchers 
who developed for the first time methods to isolate and propa-
gate human ESCs (hESCs).29 This seminal discovery ushered 
in a new era of regenerative medicine where hESCs could be 
used for the generation of functionally mature human cells, 
including cardiac tissue.
Several groups have reported the differentiation of mouse 
ESCs (mESCs)30–32 and hESCs33–36 to cardiomyocytes that 
express well-organized sarcomeric proteins and display syn-
chronous contractile activity. Further genetic and molecular 
analyses of in vitro derived cardiomyocytes have revealed that 
these cells display properties similar to early-stage, fetal car-
diomyocytes, thereby potentially limiting their therapeutic 
potential.37 In fact, several studies have evaluated the poten-
tial of ESC-derived cardiomyocytes in repairing the damaged 
cardiac tissue in animal models of MI. As such, these studies 
have shown that transplanted cardiomyocytes derived from 
both mESCs38,39 and hESCs23,40–42 integrate with host tissue 
and can lead to the improvement of cardiac function. How-
ever, there remains considerable debate as to whether these 
transplanted cells suppress43 or induce44,45 cardiac arrhythmias 
in injured hearts. Finally, additional hurdles such as complica-
tions associated with immune rejection and ethical issues may 
limit the clinical application of cardiomyocytes derived from 
hESCs.46 Despite these challenges, there are ongoing clinical 
trials assessing the feasibility and safety of a transplantation of 
hESC-derived cardiac-committed progenitor cells derived in 
patients with severe heart failure (ClinicalTrials.gov Identi-
fier: NCT02057900).
Induced pluripotent stem cells. IPSCs are PSCs generated 
through the reprograming of somatic cells into a pluripotent 
state. IPSCs were first generated by Yamanaka’s group in 
2006 from mouse fibroblasts47 and then in 2007 from human 
fibroblasts.48 Because generation of human induced pluripo-
tent stem cells (hiPSCs) does not involve the destruction of 
human embryos, they are not subject to the same ethical con-
siderations as hESCs. HiPSCs have an additional advantage 
that they do not generate an immune response in the recipi-
ent from which they were derived, although recently this has 
been subject to a considerable debate.49,50 Additionally, cardio-
myocytes generated from patient-specific cells can be used to 
provide important insights in disease pathology, progression, 
and mechanism, as well as an unlimited source of cells, and to 
enable the development of compounds and the screening of 
potential drugs.51–53
Adult stem cells. Tissue-specific adult stem cells are 
more limited in their differentiation potential compared to 
PSCs. Additionally, unlike PSCs, which can be propagated 
in culture indefinitely, adult stem cells are difficult to main-
tain and expand in vitro. Within the body, adult stem cells are 
located in complex microenvironments, called niches, which 
tightly regulate their self-renewal and differentiation.54 Adult 
stem cells have been isolated from a variety of tissues, includ-
ing the mammary glands (mammary stem cells),55 the base of 
the crypt of the intestinal epithelium (intestinal stem cells),56 
basal layer of the epidermis (epidermal stem cells),57 Subven-
tricular zone of the lateral ventricle and the subgranular zone 
of the hippocampus in the central nervous system (neural 
stem cells),58 the bulge region of the epithelial stem cells in 
the hair follicle,59 the basal layer of the seminiferous tubules 
(germline stem cells),60 under the basal lamina of myofibers 
(muscle satellite cells),61 and the bone marrow (hematopoietic 
stem cells).62 The following three additional adult stem cell 
populations have been widely used in cardiac tissue engineer-
ing applications: (i) mesenchymal stem cells (MSCs), (ii) adi-
pose-derived stem cells (ADSCs), and (iii) cardiac progenitor 
cells (CPCs).
Bone marrow-derived MSCs. MSCs are derived from the 
nonhematopoietic stromal component of the bone marrow.63,64 
Most commonly, MSCs are isolated using fluorescence- 
or magnetic-activated cell sorting with a combination of 
positive (eg, CD13, CD29, CD44, CD73, CD90, CD105, 
STRO-1) and negative (eg, CD3, CD14, CD15, CD28, 
CD33, CD34, CD45, HLA-DR) selection markers.65,66 
Several groups have shown that MSCs have the potential to 
differentiate into a variety of nonmarrow cells such as bone, 
cartilage, connective tissue fat, and endothelial cells.67 How-
ever, the existence and differentiation potential of MSCs 
has been somewhat controversial as some studies suggest 
that MSCs and fibroblasts are identical.68 Nonetheless, sev-
eral groups have reported the in vitro directed differentiation 
of MSCs to cardiomyocyte-like cells through a variety of 
approaches, including incubation with media that has been 
conditioned on primary ventricular cardiomyocytes69 and 
addition of chemical factors such as the DNA methylation 
inhibitor 5-azacytidine.70,71 Although cells generated using 
these methods express early cardiomyocyte markers such 
as cardiac myosin heavy chain (MHC), cardiac troponin T 
(cTnT), and connexin 43, in-depth electrophysiological and 
functional analyses of such resultant populations have yet to 
be reported.
Despite the lack of in vitro analysis of the cardiac dif-
ferentiation potential of MSCs, several studies have reported 
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the transplantation of MSCs or MSC-derived cardiac cells in 
animal models of cardiac damage.72–77 For example, in a study 
performed by Orlic et al, isolated MSCs were injected into 
the ventricular portion of an infarcted heart.78 The engrafted 
MSCs generated de novo myocardium and ameliorated the 
outcome of coronary artery disease in the treated animals. 
Along similar lines, transplantation of MSC-derived cardiac 
cells into a cryoinjury-derived scar in the left ventricle resulted 
in the repair of scar tissue and improved cardiac function.70
Because of the promising results observed in preclinical 
animal models of cardiac injury and disease, numerous clini-
cal trials have been performed to examine the ability of MSCs 
to ameliorate or reverse the effects of tissue damage caused 
by MI. Overall, the results of these clinical trials have been 
met with mixed success.79 Some trials have demonstrated 
that autologous MSC transplantation leads to improved ven-
tricular function and survival in patients several years after 
transplantation.80 On the other hand, recent studies have 
not shown significant improvement of ventricular function 
after either intracoronary81 or transendocardial82 delivery of 
autologous MSCs in patients with acute MI81 or ischemic 
cardiomyopathy.82
Adipose-derived stem cells. ADSCs have been isolated 
using cell sorting approaches from a variety of sources, includ-
ing human white and brown adipose tissues.83,84 Similar to 
MSCs, ADSCs have the ability to undergo osteogenesis, 
chondrogenesis, and adipogenesis. However, ADSCs may be 
advantageous over MSCs as a source of material for cell-based 
therapies because of relative ease of their isolation and abil-
ity for their long-term in vitro expansion. Several groups have 
examined the in vitro ability of ADSCs to differentiate into 
cardiomyocytes.85–87 For example, Planat-Bénard et al dem-
onstrated that the addition of 5-azacytidine to ADSC cultures 
resulted in cells that expressed cardiac-specific markers such as 
GATA4, NKX2.5, ANP, MLC2v, and MLC2a.85 Addition-
ally, ultrastructural and electrophysiological analyses revealed 
the presence of functional atrial, ventricular, and nodal car-
diomyocytes. Similarly, other groups have shown that modu-
lation of soluble signaling pathways such as Wnt/β-catenin87 
and vascular endothelial growth factor88 enhances the cardiac 
differentiation of ADSCs. On the other hand, some argue 
that ADSCs lack inherent cardiac differentiation potential89 
and that only through direct fusion with primary cardiomyo-
cytes can ADSCs display cardiomyocyte-like phenotypes.90
In subsequent studies in animal models of cardiac dam-
age, delivery of ADSCs through direct intramyocardial injec-
tion91 or indirectly through intravenous92 or intracoronary93 
injections has resulted in the repair of damaged myocardial 
tissue and improved cardiac function. A clinical trial exam-
ining the effects of transendocardial injections of ADSCs 
in patients with nonrevascularizable ischemic myocardium 
demonstrated that ADSC-treated patients showed significant 
improvements in total left ventricular mass and reductions in 
inducible ischemia. Additionally, these studies revealed that 
ADSCs preserved ventricular function, myocardial perfusion, 
and exercise capacity in ischemic patients.94 Additional ongoing 
clinical trials are examining the safety and efficacy of ADSCs 
in patients with chronic myocardial ischemia (Clinical-
Trials.gov Identifiers: NCT02052427, NCT01556022, and 
NCT01449032).
Cardiac progenitor cells. Several studies over the past 
decade have demonstrated the existence of a CPC popula-
tion that can contribute to cardiac tissue homeostasis and 
repair.46,95–98 CPCs can be isolated from functionally mature 
cardiac tissue using a variety of cell surface markers, including 
c-Kit,95 Sca-1,96 CD31,97 Flk-1,99 Flt1+/Flt4+,98 or on the 
ability to efflux Hoechst dye.100 Although there is a lack 
of consensus of the specific markers that should be used to 
isolate CPCs from primary tissue,101 CPCs share the follow-
ing common characteristics: (i) express early cardiac markers 
(eg, GATA4, NKX2.5), (ii) can be expanded in vitro through 
modulation of various pathways such as Wnt/β-catenin102,103 
and FGF104 signaling, and (iii) are capable of generating 
the three major cell types that comprise the myocardium – 
cardiomyocytes, smooth muscle, and endothelial cells. As it 
relates to in vitro generation of cardiomyocytes, treatment of 
CPCs with 5-azacytidine or other signaling molecules such 
as TGF-β results in cells that express cardiomyocyte-related 
sarcomeric proteins (eg, β-MHC, a-actinin), contract sponta-
neously, and display action potentials that resemble those of 
mature cardiomyocytes.97,99,105 Although CPCs robustly dif-
ferentiate into cardiomyocytes in vitro, there is considerable 
debate to the extent to which endogenous CPCs contribute to 
cardiomyocytes in the heart.106–110
The therapeutic potential of CPCs has been extensively 
studied in animal models of cardiac damage and disease. For 
example, Dawn et al demonstrated that intravascular injection 
of CPCs results in increased cardiac mass and ventricular func-
tion during hypertrophy or ischemia.111 Along similar lines, it 
has been reported that in aortic stenosis112 and ischemic heart 
failure,113 the activation of endogenous CPCs results in myo-
cyte formation and myocardial regeneration.
There are several early clinical trials that are examining 
the ability of CPCs to ameliorate the effects of cardiac injury 
and disease. In one such trial, autologous CPCs were delivered 
through intracoronary injections in patients with postinfarction 
left ventricular dysfunction.114 Patients examined one year after 
treatment showed a significant increase in ventricular function 
and decrease in infarct size. In a similar study, autologous CPCs 
isolated from endomyocardial biopsies were infused into the 
infarct-related artery of patients who suffered an MI.115
Classes of biomaterials for Stem Cell Cardiac Muscle 
Repair
A variety of biomaterial scaffolds have been used for the in vitro 
generation of stem cell-derived cardiac tissue and the in vivo 
delivery of stem cells to damaged myocardium. These biomate-
rials can be classified into the following categories (Table 2).
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extracellular matrix protein-based biomaterials. 
Extracellular matrix protein (ECMP)-based biomaterials are 
attractive scaffolds for cardiac tissue engineering and regen-
eration because they retain their inherent biological activity to 
support cell adhesion, survival, and differentiation. These bio-
materials include those isolated from animal sources, such as 
Matrigel™ and Geltrex™, and those from purified or recom-
binant sources, such as collagen, laminin, fibronectin, and vit-
ronectin.116–118 ECMP-based biomaterials are biocompatible 
and can be proteolytically degraded into nontoxic by-products. 
In addition, the degradation rate of ECMP-based materials 
is highly variable and dependent upon several factors such as 
implantation location and extent of material cross-linking.119 
As an example, biomaterials composed of gelatin, a denatured 
derivative of collagen, have a higher degradation rate than col-
lagen itself.119
decellularized matrices. Although ECMP-based 
materials can be used as stem cell substrates, they do not 
readily mimic the complexity and architecture of native tis-
sue. On the other hand, it has been demonstrated that decel-
lularized matrices, which can be readily obtained through 
the detergent treatment of intact cardiac tissue,120 retain the 
complex mixture of collagens, elastin, and glycosaminogly-
cans that comprise in vivo tissue.121 As such, these decellular-
ized matrices, which maintain the composition and structure 
of in vivo tissue, have gained a wide use in cardiac regenera-
tive medicine purposes.121 Similar to ECMP-based bioma-
terials, decellularized matrices are degraded in vivo into safe 
by-products.122
Natural biomaterial scaffolds. Several naturally occur-
ring biomaterials have been used for in vitro and in vivo cardiac 
regenerative medicine purposes. These naturally occurring 
materials are advantageous because they contain the proteins, 
polysaccharides, and other cell adhesive domains that are 
found in native tissue. Naturally occurring biomaterials that 
have been used in cardiac tissue engineering include silk fibroin 
(biodegradable polypeptide secreted from worms and insects), 
chitosan (polysaccharide-based material isolated from crusta-
cean shells), fibrin (generated through the polymerization of 
the protein fibrinogen isolated from blood plasma), alginate 
(polysaccharide-based material obtained from brown algae), 
and agarose (polysaccharide-based material obtained from red 
algae).123–130 The physicochemical properties of these natural 
biomaterials can be manipulated, so that they can be naturally 
degraded within days to weeks after implantation.119,124,131 
As such, when implanted in vivo, these materials will persist 
long enough to promote integration with the native tissue but 
degrade quickly enough not to disrupt mechanical coupling 
that is critical to myocardial function.132
Synthetic polymer-based materials. Several synthetic 
polymer-based materials have been used for cardiac regen-
erative medicine purposes.133 Compared to ECMPs and 
decellularized scaffolds, polymer-based materials are easily 
fabricated and tunable, thereby allowing iterative engineering 
of materials for specific stem cell responses. Polymers that 
have been used for stem cell-based cardiac tissue enginee ring 
include poly(ethylene glycol) (PEG), poly(lactic acid) 
(PLA), poly (caprolactone) (PCL), poly(l-lactide-co-caprolactone) 
(PLCL), poly(glycolide-co-caprolactone) (PGCL), poly(glycerol 
sebacate) (PGS), and polyurethane (PU).134–140 While some 
polymer-based biomaterials such as PGS,141,142 PLCL,143 
and PGCL144 biodegrade into nontoxic natural metabolites 
over the course of several weeks or months,143 other polymer-
based materials can release potentially harmful by-products 
of degradation. For example, it has been demonstrated that 
PU-based biomaterials can oxidize, thereby leading to post-
implantation complications.145 To that end, modifications, 
such as coating PU-based materials with an antioxidant 
layer, have been shown to reduce adverse degradation effects 
in vivo.145
Application of biomaterials to Aid in Vitro 
differentiation of Stem Cells to Cardiac Tissue
The development of reproducible and efficient methods for 
differentiating stem cells to functionally mature cardiomyo-
cytes in vitro is a necessary step for the application of these 
cells for disease modeling, drug screening, and regenerative 
medicine purposes. In this section, we will review the current 
biomaterial-based approaches that are being implemented to 
guide the differentiation of adult stem cells and PSCs toward 
cardiomyocytes.
eCMP-based biomaterials. ECMP-based materials 
have been used as matrices for the cardiac differentiation of 
a variety of stem cell types. Cardiogel, a naturally occurring 
extracellular matrix (ECM) containing a complex mixture of 
laminin and fibronectin isolated from cardiac fibroblasts,146 has 
been used to direct the differentiation of MSCs to cardiomyo-
cytes.147 ECMPs from both purified and recombinant sources 
have also been used as natural biomaterials for the generation 
of cardiomyocytes from stem cell populations. For example, 
Santiago et al examined the effect of individual ECMPs, 
including collagens type I, III, IV, laminin, and fibronectin, 
on the cardiac commitment of MSCs.148 The authors found 
that collagen can be remodeled to form fibrils that guide the 
differentiation of MSCs into cells representative of cardiac 
muscle.148 Along similar lines, Miskon et al reported that 
differentiation of MSCs on collagen type I matrix elevated 
expression of cardiomyocyte-related genes in the resultant 
populations.149 Likewise, Tan et al reported that MSCs dif-
ferentiated on collagen V matrices had higher expression of 
cardiac-related genes such as GATA4, NKX2.5, and cTnT 
compared to cells differentiated on collagen I matrices.150 In 
fact, cardiac cells generated on collagen V matrices prevented 
chamber dilation and improved contractile function when 
injected into the injured myocardium of animals subject to an 
MI.150 On the other hand, other nonfibrillar ECMPs such as 
laminin have been shown to facilitate the differentiation of 
ADSCs toward cardiomyocytes.151
Cutts et al
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Natural biomaterial scaffolds. Silk fibroin substrates 
have been used extensively for the cardiac differentiation of 
adult stem cell populations. In one such study, silk fibroin 
nanometric nets were fabricated and seeded with CPCs.162 
After three weeks of culture, CPCs differentiated into cells 
that expressed high levels of cardiac- and sarcomeric-related 
proteins.162 In fact, these scaffolds not only induced alignment 
of the cardiomyocyte populations but also synthesis of titin, 
a protein critical to sarcomere assembly.
Polysaccharide-based scaffolds have also been imple-
mented for cardiac differentiation of stem cell populations.163–165 
For example, Liu et al demonstrated that chitosan substrates 
enhanced the cardiomyogenic potential of ADSCs when com-
pared to cells cultured on standard tissue culture polystyrene 
substrates.163 In a related study, chitosan elevated intracellular 
calcium levels in differentiating ADSCs, thereby significantly 
upregulating the expression of cardiac marker genes GATA4, 
NKX2.5, and MYH6.164 Along similar lines, another 
polysaccharide-based material, alginate, preserved the cardiac 
differentiation potential of CPCs.166
Composite biomaterials have also been investigated 
for their effect on the cardiac differentiation potential of 
MSCs.167,168 To that end, Yang et al found that MSCs more 
efficiently differentiated to cardiac cells when cultured on 
hybrid substrates consisting of silk fibroin and hyaluronic 
acid when compared to cells differentiated only on silk fibroin 
matrices.168 The same group found that by incorporating the 
polysaccharide chitosan into these silk fibroin/hyaluronic acid 
scaffolds significantly elevated the cardiomyogenic differen-
tiation of MSCs.
Fibrin-based scaffolds have been widely used for the 
cardiac differentiation of PSCs.169–171 As an example, highly 
functionalized heart tissue was engineered by differentiat-
ing hESCs in a fibrin substrate.170 Specifically, differentiated 
cells displayed highly organized and oriented networks of sar-
comeres, as well as electrophysiological properties indicative 
of mature cardiomyocytes. Additional studies have demon-
strated that the effect of fibrin on the cardiac differentiation of 
mESCs and hESCs is improved in a 3-D culture system.169,171 
For instance, Zhang et al investigated the effects of dimen-
sionality of fibrin constructs on the structural and functional 
maturation of hESC-derived cardiomyocytes.171 Compared 
to cardiomyocytes generated in two-dimensional fibrin sub-
strates, cardiomyocytes generated in 3-D scaffolds exhibited 
significantly higher conduction velocities, longer sarcomeres, 
and elevated expression of genes involved in cardiac contrac-
tile function.171
Synthetic polymer-based materials. A variety of polymer- 
based materials have been engineered for the differentiation 
of adult stem populations toward the cardiac lineage. In a 
recent work, PU, 3-hydroxybutryate-co-4-hydroxybutryate 
[P(3HB-co-4HB)], and polypropylene carbonate (PPC) sub-
strates were studied for their ability to support the adhe-
sion and cardiac differentiation of MSCs.172 The authors 
The differentiation of hESCs toward cardiomyocytes 
has been achieved by culture on gelatin,21,152,153 cardiogel,154 
and Matrigel,155 a gelatinous protein mixture secreted by 
mouse sarcoma cells, which consists mainly of collagen, 
laminin, and entactin.156 In another line of investigation, 
Burridge and colleagues investigated the use of defined 
ECMP-based matrices for the cardiac differentiation of 
hiPSCs.157 While there was no difference in cardiomyocyte 
differentiation efficiency between recombinant laminin, 
fibronectin, and vitronectin matrices, recombinant laminin 
substrates did aid in the adhesion and survival of iPSC-
derived cardiomyocytes.
Three-dimensional (3-D) architecture has been incor-
porated into ECMP-based materials to improve the gen-
eration of cardiomyocytes from PSCs. In one such study, 
hESCs and hiPSCs were differentiated between a Matri-
gel matrix sandwich. Differentiation of cells in this system 
resulted in cardiomyocyte preparations of high purity (up 
to 98%) and yield (up to 11 cardiomyocytes for each input 
PSC).19 Additionally, the cardiomyocyte populations were 
functionally mature and displayed action potentials typi-
cal of nodal, atrial, and ventricular cardiomyocytes. More 
recently, polydimethylsiloxane (PDMS) templates were used 
to engineer collagen-based 3-D, self-assembled scaffolds, 
termed biowires, for the generation of cardiomyocytes from 
hESCs and hiPSCs.158 Differentiation of PSCs in these 
scaffolds resulted in aligned cardiac tissue with a high degree 
of ultrastructural organization, enhanced conduction veloc-
ity, and improved calcium handling and electrophysiological 
characteristics when compared to cardiomyocytes generated 
using conventional approaches.
decellularized matrices. Decellularized matrices have 
been implemented to enhance the cardiac differentiation of 
MSCs, ADSCs, and CPCs. For example, decellularized ven-
tricular ECMs have been used to enhance CPC maintenance, 
expansion, and differentiation.9 In another study, decellular-
ized full thickness ventricular matrices were repopulated with 
MSCs and human umbilical vein endothelial cells to engineer 
fully vascularized cardiac tissue.159
Likewise, decellularized heart ECMs have been used 
for in vitro generation of cardiomyocytes from hESCs and 
mESCs.120,160 In fact, these native tissue matrices increased 
the sarcomeric organization and enhanced the maturation 
of hESC-derived cardiomyocytes when compared to con-
ventional cell culture coatings such as gelatin or collagen.120 
Hybrid materials consisting of ECMPs and decellularized 
cardiac ECM have also been used to direct the differentia-
tion of hESCs to cardiomyocytes.161 For example, compos-
ite hydrogels composed of collagen type I and decellularized 
matrix from porcine heart were used to efficiently differenti-
ate hESCs to cardiomyocytes.161 Interestingly, decellularized 
hydrogels with a high collagen content promoted the function 
and contractile activities of cardiomyocytes compared with 
low collagen content or pure collagen gels.161
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found that substrates composed of PU and P(3HB-co-4HB) 
permitted optimal cell growth and cardiac differentiation. 
In another study, PCL carbon nanotube composite scaffolds 
were used to enhance cardiac differentiation of MSCs.173 
Moreover, MSCs cultured on the composite scaffolds inher-
ently assumed an elongated morphology allowing the cells 
to be more receptive to cardiac inducing factors. Additional 
PCL-based copolymer scaffolds have been used as an effec-
tive means to direct the cardiac differentiation of MSCs. For 
example, differentiation of MSCs on PLA-co-PCL scaffolds 
resulted in elevated expression of cardiac-related genes, alpha 
actinin, and MHC.174 Finally, composite scaffolds consisting 
of polymers and ECMPs have been used for the cardiogenic 
differentiation of MSCs.175 MSCs differentiated on PGS-
collagen hybrid scaffolds more efficiently differentiated to 
cardiomyocyte-like cells than cells differentiated on substrates 
that only contained collagen.175
Synthetic polymer-based materials have also been used 
for the derivation of mature cardiac cells from CPCs. PGS 
has been used to develop biomimetic substrates that guide the 
adhesion, growth, and differentiation of CPCs.176 Along sim-
ilar lines, PEG has been used to generate in vitro CPC niches 
to control their function and fate.177 These highly anisotropic 
substrates augmented CPC adhesion, migration, and prolifer-
ation. In turn, these substrates enhanced the differentiation of 
CPCs to mature cardiomyocytes through a nanotopography 
response mediated via p190RhoGAP.
Along similar lines, synthetic polymer-based substrates 
have been used for the cardiac differentiation of PSCs. As an 
example, the culture of hESCs on graphene-based polymer scaf-
folds enhanced their cardiomyogenic differentiation compared 
with differentiation on Matrigel substrates.178 In an effort to pre-
cisely tune the polymer physicochemical properties required for 
cardiac differentiation of mESCs, Gupta et al prepared a com-
binatorial polymer library by copolymerizing PEG, PCL, and 
carboxylated PCL (CPCL) and used electrospinning to develop 
scaffolds to mimic the ECM network.179 Through measure-
ment of a-myosin heavy chain (a-MHC) expression and calcium 
(Ca2+) signaling dynamics, the authors observed that the most 
compliant substrate tested, 4%PEG–86%PCL–10%CPCL, 
allowed for the most efficient cardiac differentiation of mESCs. 
Additionally, by altering the elastic modulus of the 4%PEG–
86%PCL–10%CPCL substrates, the authors were able to fur-
ther promote maturation of mESC-derived cardiomyocytes.
Hybrid scaffolds consisting of polymers, ECMPs, and 
other materials have been implemented as an effective means 
to direct the fate of hESCs toward cardiomyocytes. For exam-
ple, poly(lactic-co-glycolic acid) (PLGA) and collagen scaffolds 
were fabricated using electrospinning methods to precisely 
control the fiber diameters to mimic the ECM of in vivo car-
diac tissue.180 Differentiation of hESCs to cardiomyocytes on 
the composite PLGA/collagen scaffolds was found to be more 
efficient than on the substrates composed solely of PLGA or 
collagen.
biomaterial-based Methods for the In Vivo delivery 
of Stem Cell Populations to Repair Cardiac Tissue
Current methods of stem cell delivery for cardiac regenera-
tive purposes are inadequate as the integration and survival 
of transplanted cells is low, thereby reducing their therapeutic 
potential.181,182 As such, biomaterial scaffolds have emerged 
as a promising approach to effectively deliver stem cells to 
damaged cardiac tissue. The following design considerations 
must be taken into account when implementing biomaterial-
based approaches for the delivery of stem cells to repair car-
diac tissue: (i) provide the appropriate strength and elasticity 
to withstand contraction and relaxation (or cyclic stretch) of 
the myocardium, (ii) capable of biodegrading without the gen-
eration of any toxic products once new tissue is formed, and 
(iii) conducive to support the contraction, proliferation, and 
differentiation of stem cells and their derivatives. In this sec-
tion, we will review the various biomaterial-based approaches 
that are being used to deliver stem cells to repair injured or 
diseased myocardium.
eCMP-based biomaterials. Collagen-based scaffolds 
have been widely implemented as an efficient means to deliver 
stem cells to damaged myocardial tissue.183–186 In fact, it has 
been reported that the use of collagen as a stem cell delivery 
vehicle significantly reduced the localization and engraftment 
of transplanted cells to other organs and uninjured myocar-
dium.183 Collagen-based matrices have been used to deliver 
MSCs to damaged cardiac tissue in animal models of MI. For 
example, a patch consisting of autologous MSCs seeded in a 
collagen scaffold that was engrafted into the epicardial sur-
face of a chronic MI scar led to enhanced angiogenesis and 
significantly improved cardiac function.184 In a related study, 
Simpson et al demonstrated that the delivery of MSCs using 
such methods led to elevated ventricular remodeling and 
function compared to MSCs delivered through direct injec-
tion.185 Addition of glycosaminoglycans to these MSC seeded 
collagen scaffolds has led to improved cell retention, neovas-
cularization, and tissue repair.187
The use of collagen scaffolds for cell delivery has not 
been limited to use with only MSCs. Araña et al examined 
the effect of collagen patches seeded with ADSCs on cardiac 
function in models of chronic MI.188 The delivery of ADSCs 
in collagen substrates led to increased cell engraftment as well 
as improvement in cardiac function, myocardial remodeling, 
and revascularization. Moreover, the level of fibrosis, a fac-
tor that critically impairs cardiac recovery in chronic MI, was 
significantly reduced in animals that received ADSC seeded 
collagen patches.
Matrigel has been used as a substrate to deliver PSCs 
and their derivatives to sites of cardiac damage. Kofidis et al 
used Matrigel scaffolds to deliver undifferentiated mESCs 
to the damaged ventricular areas of a postinfarcted heart.189 
Overall, the mESC seeded scaffold engrafted within the 
injured area and prevented ventricular wall thinning. Impor-
tantly, no signs of teratoma formation were reported, and the 
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engrafted cells remained viable and expressed high levels of 
the cardiomyocyte-related proteins, connexin 43 and alpha-
sarcomeric actin.
decellularized matrices. Because of the ability to match 
the biochemical properties of native heart tissue, decellularized 
matrices are emerging as a promising approach to deliver stem 
cells to regions of cardiac damage. Additionally, it has been 
shown that when delivered to the in vivo heart tissue, these 
scaffolds have the potential to promote stem cell differentia-
tion, cardiac regeneration, and angiogenesis.190 Lesman and 
colleagues used decellularized matrices and hESC-derived 
cardiomyocytes as the basis for the engineering of 3-D tissue-
engineered cardiac muscle.191 Upon transplantation to the 
heart, the engineered muscle formed cardiac tissue grafts and 
integrated with the host coronary vasculature. In the future, 
such engineered tissue could be used to ameliorate or reverse 
the effects of cardiac damage.
Natural biomaterial scaffolds. Fibrin-based scaffolds have 
been effectively used to improve adult stem cell engraftment and 
survival in cardiac regenerative medicine applications. Embed-
ding ADSCs in fibrin scaffolds leads to improved ventricular 
function and remodeling in a model of acute MI when com-
pared to direct ADSC implantation.192 Along similar lines, Guo 
et al demonstrated that the delivery of CPCs in fibrin matri-
ces promoted their survival, engraftment, and cardiomyogenic 
differentiation in an animal model of MI.193 In turn, improved 
myocardial tissue repair and cardiac function were observed in 
animals that received CPCs delivered in fibrin scaffolds com-
pared to the animals that received CPCs or fibrin alone.
Polysaccharide containing matrices have been broadly 
used as adult stem cell delivery vehicles. Encapsulation of 
MSCs194–196 or ADSCs197 in alginate enhanced retention and 
survival of MSCs in several animal models of MI. As such, 
alginate encapsulation facilitated paracrine effects, such as 
increased angiogenesis and decreased scaring, and improved 
cardiac function.195 Similarly, Wang and colleagues dem-
onstrated that delivery of ADSCs in chitosan hydrogels to 
regions of the heart that had been damaged by MI enhanced 
cell survival and increased differentiation to cardiomyo-
cytes.165 Moreover, cell delivery in chitosan prevented adverse 
matrix remodeling, elevated angiogenesis, and preserved car-
diac function. Interestingly, a direct comparison of alginate 
and chitosan matrices revealed that the delivery of ADSCs in 
alginate scaffolds improved cell retention in the infarcted heart 
when compared to chitosan scaffolds.198 In order to leverage 
the beneficial effects of both alginate and chitosan, Ceccaldi 
et al examined the efficacy of MSCs seeded in composite scaf-
folds that comprised various alginate/chitosan ratios in ame-
liorating the effects of acute MI.199 The authors found that an 
alginate/chitosan ratio of 40/60 led to the highest improve-
ment in cardiac function and attenuation of fibrosis.
The application of PSCs and their derivatives for in 
vivo cardiac repair have benefited from the use of natural 
biomaterial scaffolds as delivery vehicles. For example, the 
transplantation of hESC-derived cardiomyocytes in photo-
crosslinkable PEGylated-fibrinogen matrices led to increased 
ventricular performance in a MI model.200 Along similar 
lines, several studies have demonstrated that fibrin scaffolds 
loaded with hESC-derived cardiac cells and mESC-derived 
cardiac cells can reverse the fibrotic effects of MI and lead 
to improved ventricular function when delivered to regions of 
cardiac damage.201–203 Finally, the coinjection of mESCs and 
hESCs in polysaccharide-based scaffolds such as alginate and 
chitosan in infarcted heart tissue has led to the generation of 
new myocardium and preservation of cardiac function.204,205
Synthetic polymer-based materials. Owing to the 
ability to tailor their physicochemical properties, synthetic 
polymer-based materials have been widely implemented as 
scaffolds for the in vivo delivery of stem cells for cardiac tis-
sue engineering purposes. For instance, bioengineered polyg-
lycolic acid (PGA) cloths seeded with MSCs have been used 
to induce angiogenesis and improve function in an infarcted 
heart.206 In a related study, transplantation of MSCs within 
PLCL scaffolds reduced scar size and improved cardiac func-
tion in an animal model of MI.207 Similarly, MSCs seeded in 
PLCL scaffolds that were injected into infarcted cardiac tissue 
migrated to damaged myocardium, augmented neovascular-
ization, and improved ventricular function.208
Several injectable biodegradable hybrid materials have 
been engineered for cardiac tissue engineering applications. 
For example, Xu et al developed a hydrogel that comprised thi-
olated collagen and oligo(acryloyl carbonate)-b-poly(ethylene 
glycol)-b-oligo(acryloyl carbonate) (OAC-PEG-OAC) for the 
encapsulation of MSCs to be used for cardiac regeneration 
purposes.209 As such, these composite hydrogels combined 
the intrinsic biological activity of collagen and the structural 
integrity of the OAC-PEG-OAC polymers. When used in 
an infarction model, these hybrid hydrogels reduced infarct 
size, increased ventricular wall thickness, and improved car-
diac function. In a similar study, the intramyocardial delivery 
of MSCs in silanized poly(hydroxypropyl) methylcellulose 
hydrogels attenuated ventricular remodeling and rescued car-
diac function in a model of MI.210
Polymer-based scaffolds have also been used for the 
delivery of PSCs and their derivatives to regions of damaged 
myocardial tissue. In one such study, a heart patch was engi-
neered from the synthetic elastomer PGS that was seeded 
with hESC-derived cardiomyocytes.211 Upon suture over the 
left ventricle, these patches remained intact over a two-week 
period without any negative impacts on ventricular function. 
In the future, such patches could be used for stem cell-based 
cardiac regeneration strategies.
Future Trends and Techniques in biomaterial-
based Approaches for Stem Cell Myocardial Tissue 
engineering
One of the main challenges that need to be addressed to 
move stem cell-based approaches for cardiac regeneration 
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from bench-to-bedside is enhancing the survival, engraft-
ment, and differentiation of cells in the ischemic or fibrotic 
host tissue.212 One emerging approach to overcome this hurdle 
is to engineer biomaterial-based systems for the dual delivery 
of pro-survival soluble signaling cocktails and stem cells to 
regions of damaged myocardium. For example, thermosensi-
tive N-isopropylacrylamide (NIPAAm) hydrogels have been 
engineered to release bFGF for the enhanced differentiation 
of MSCs into cardiomyocyte-like cells under ischemic con-
ditions.213 Karam and colleagues developed a PLGA-based 
system that could be used to encapsulate ADSCs along with 
two cardiac inducing growth factors, hepatocyte growth fac-
tor and insulin-like growth factor (IGF-1).213 The authors dem-
onstrated that sustained release of hepatocyte growth factor 
and IGF-1 enhanced the cardiac differentiation of encapsu-
lated ADSCs. Similarly, encapsulation of CPCs in an alginate 
hydrogel containing superoxide dismutase, a reactive oxygen 
species scavenger, prevented doxorubicin-induced apoptosis.214 
Finally, biomaterial-based scaffolds loaded with prosurvival and 
proangiogenic factors such IGF-1 and thymosin β4 have been 
used to deliver hiPSCs and their derivatives to infarcted cardiac 
tissue.215 In fact, the use of such scaffolds led to reduced infarct 
size and the formation new vasculature in the host tissue. In the 
future, engineered biomaterials to deliver stem cells along with 
pro-survival drugs may enable sustained tissue preservation and 
potentially promote regeneration of ischemic cardiac tissue.134
Another emerging approach for the stem cell-based 
repair of ischemic tissue is the use of biomaterials to develop 
pre-vascularized tissues that can be delivered via surgery to 
sites of cardiac injury. To that end, Pagliari et al developed a 
multistep procedure to engineer pre-vascularized 3-D cardiac 
bio-substitutes.216 Specifically, MSCs and CPCs were seeded 
in a highly porous biocompatible gelatin scaffold. Exposure of 
the scaffold to fluid flow within a modular bioreactor stimu-
lated the formation of VCAM-1-positive vascular cells form-
ing tube-like structures around the scaffold and pores, which 
contact cTnT expressing cardiomyocytes. One could imagine 
that in the future such vascularized constructs could intercon-
nect with host vasculature and be used to stimulate repair of 
damaged in vivo cardiac tissue.
In the future, the ability to effectively move biomaterial 
approaches for stem cell-based myocardial tissue engineering 
from bench-to-bedside will require limiting the potential for 
complications in patients. For example, while recent progress 
has been made in the directed differentiation of human pluri-
potent stem cells (hPSCs) to immature myocardial cell types,26 
these protocols yield a heterogeneous cell population consist-
ing of nodal-, atrial-, and ventricular-like CM subtypes.36,217 
As such, these heterogeneous populations have displayed a 
high degree of arrhythmogenic properties, thereby potentially 
limiting their clinical application.44,45 Before such cell types 
can be used in patients, reproducible methods for the genera-
tion of homo genous, subtype-specific CMs need to be devel-
oped. Another challenge of stem cell-based cardiac therapies 
is the high potential for allogenic immune rejection by recipi-
ents.218 To that end, continued advances in directed genome 
modification may allow for the generation of stem cell-derived 
cardiac tissue that evades allogenic immune responses.219
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